Abstract: Background: Abnormalities in dopamine (DA) and brain morphology are observed in several neuropsychiatric disorders. However, it is not fully understood how these abnormalities may relate to one another. For such in vivo findings to be used as biomarkers for neuropsychiatric disease, it must be understood how variability in DA relates to brain structure under healthy conditions. We explored how the availability of striatal DA D 2/3 receptors (D 2/3 R) is related to the volume of subcortical brain structures in a sample of healthy humans. Differences in D 2/3 R availability measured with an antagonist radiotracer ([ 
INTRODUCTION
Elucidating neurochemical and structural brain changes associated with mental disorders remains a critical challenge for the development of robust "biomarkers" in psychiatry [Perlis, 2011] . However, it remains poorly understood how in vivo differences in neurochemistry relates to variation in brain structure. For example, while it has been demonstrated that persons with schizophrenia have increased endogenous dopamine (DA) levels in the striatum [Abi-Dargham et al., 2000; Caravaggio et al., 2015b; Kegeles et al., 2010] , this has yet to be associated with any of the morphological brain changes observed in this disorder [Ellison-Wright et al., 2008; Haijma et al., 2013; Rimol et al., 2010; Song et al., 2015; van Erp et al., 2016; Xiao et al., 2015] . Similarly in obesity, while changes in DA D 2/3 receptor (D 2/3 R) availability [Caravaggio et al., 2015c; Dang et al., 2016; Gaiser et al., 2016; Guo et al., 2014; Karlsson et al., 2016; Mawlawi et al., 2001 ] and brain morphology [Bond et al., 2011; Taki et al., 2008; Veit et al., 2014; Walther et al., 2010] have been observed, these changes have yet to be directly associated with each other [Karlsson, 2016] . Thus, the use of in vivo DA functioning and brain morphology as biomarkers for disease remains hindered insofar as it is not firmly established how they may relate to one another under normal conditions [Strimbu and Tavel, 2010] .
While several animal studies have examined the effect of altering DA levels on brain development [Alvarez et al., 2002; Jones et al., 1996; Kalsbeek et al., 1989; Meredith et al., 1995; Pappas et al., 1992; Reinoso et al., 1996] , few human studies have examined how in vivo DA functioning, measured with positron emission tomography (PET), relates to brain morphology [Casey et al., 2013; Morales et al., 2015; Werhahn et al., 2006; Woodward et al., 2009] . Using voxel-based morphology and the antagonist radioligand [ 18 F]-fallypride, Woodward et al. were the first to examine how variations in brain morphology relates to D 2/3 R availability in healthy persons [Woodward et al., 2009] . They observed that D 2/3 R availability within a given brain region was generally positively correlated with the gray matter (GM) density/volume of that region (e.g., within the caudate, thalamus, amygdala, and substantia nigra). This generally suggests that, (i) D 2/3 R availability may vary positively with the amount of GM, and/or, (ii) differences in D 2/3 R availability may alter brain structure during development [Woodward et al., 2009] . However, negative correlations [Woodward et al., 2009] , and null correlations [Werhahn et al., 2006] 18 F]-fallypride, midbrain D 2/3 R availability was also found to be positively correlated with GM volume in the striatum, prefrontal cortex, insula, hippocampus, and temporal cortex of methamphetamine users, but not healthy controls [Morales et al., 2015] . Finally, using [ 11 C]-raclopride, it has been demonstrated that striatal DA release in response to amphetamine is negatively correlated with frontal lobe thickness in healthy controls [Casey et al., 2013] .
Previous studies have not systematically examined how striatal D 2/3 R availability is related to subcortical morphology in healthy persons. Moreover, previous studies have only used antagonist radiotracers for D 2/3 R, that is, [
F]-fallypride and [
11 C]-raclopride. It is generally believed that D 2/3 R exist in (at least) two conformational states for agonist binding: an active state (D 2 High) and an inactive state (D 2 Low) [Seeman, 2011] . In theory, agonist radiotracerssuch as [ 11 C]NPA [Narendran et al., 2004] [Freedman et al., 1994; Gallezot et al., 2012; Rabiner et al., 2009; Searle et al., 2010; Seeman et al., 1993] , results in a differential contribution of D 2 R and D 3 R to the [ 11 C]-(1)-PHNO signal across different regions of interest (ROIs). The estimated percent of the [ 11 C]-(1)-PHNO signal attributed to D 3 R across ROIs in humans are: substantia nigra (100%), globus pallidus (GP, 65%), ventral striatum (VS, 26%), and dorsal caudate-putamen (negligible) [Graff-Guerrero et al., 2010; Searle et al., 2013b; Tziortzi et al., 2011] . Also, as an agonist, baseline [
11 C]-(1)-PHNO binding to D 2/3 R is more sensitive to competition with endogenous dopamine in vivo in humans [Caravaggio et al., 2014 [Caravaggio et al., , 2016a Shotbolt et al., 2012] . Thus, it remains unknown how D 2/3 R availability measured with an agonist radiotracer, and how D 3 R availability specifically, may be related to brain morphology.
In the current investigation, we sought to explore how D 2/3 R availability measured with the antagonist radiotracer [
11 C]-raclopride and the agonist radiotracer (1)-PHNO is related to subcortical brain volume in healthy persons. We specifically examined the volume of (i) striatal subdivisions, (ii) hippocampal subdivisions, (iii) thalamic subdivisions, and (iv) the amygdala. This investigation marks an important first step in elucidating how in vivo differences in dopaminergic functioning may relate to subcortical brain morphology. A better understanding of these relationships will help inform the use of neurochemical and structural brain changes as potential biomarkers for neuropsychiatric disease.
METHODS

Participants
Healthy control data from a previous study were reanalyzed for the current investigation [Nakajima et al., 2015] . This sample comprises data collected by our laboratory from various PET studies [Caravaggio et al., 2015b; Graff-Guerrero et al., 2008 Payer et al., 2014] that were approved by the Research Ethics Board of the Centre for Addiction and Mental Health (CAMH), Toronto. For the current investigation, subjects were included if they provided a T1 structural MRI (1.5T or 3T), and an [
The participants were right-handed and free of any major medical or psychiatric disorder as determined by clinical interview, the MiniInternational Neuropsychiatric Interview, and electrocardiography. Current or past alcohol abuse was an exclusion criteria. Participants were required to provide a full urine drug screen, and produced a negative urine screen for drugs of abuse and/or pregnancy at inclusion and before the PET scan. This included ethyl alcohol. Before the scan, the aural temperature and blood pressure of the participants were measured to insure they were within normal limits. All participants provided written informed consent and were non-smokers.
MRI Imaging
Fifty-one subjects scanned with [
11 C]-raclopride and 58 subjects scanned with [ 
Subcortical Volume Analyses
The Multiple Automatically Generated Templates (MAGeT-Brain) algorithm Pipitone et al., 2014] was used to provide fully-automated segmentation of striatal subdivisions [Chakravarty et al., 2006] , hippocampal subdivisions [Pipitone et al., 2014; Winterburn et al., 2013] , thalamic subdivisions [Chakravarty et al., 2006 [Chakravarty et al., , 2008 [Chakravarty et al., , 2009 , and the amygdala [Treadway et al., 2015] . Typically, in a multi-atlas segmentation approach, manually drawn labels from atlases are warped (or propagated) into subject space by applying transformations estimated from non-linear image registration. Candidate labels from all atlas images are fused (via probabilistic segmentation techniques) to create a final segmentation. The goal of the MAGeT-Brain algorithm is to mitigate sources of error from such approaches including: (1) spurious non-linear registration or resampling errors (including partial volume effects [PVE] in label resampling), and (2) irreconcilable differences in neuroanatomy between the atlas and target images. The MAGeT-Brain algorithm is a modified multi-atlas segmentation technique, which uses a limited number of high-quality manually segmented atlases as an input to reduce bias and enhance segmentation accuracy. MAGeT-Brain propagates atlas segmentations to a template library, formed from a subset of target images, via transformations estimated by nonlinear image registration. The resulting segmentations are then propagated to each target image and fused using a label fusion method. Specifically, for those subjects who provided a 1.5T MRI, subsets of subjects scanned with [ 11 C]-raclopride (n 5 21) and [ 11 C]-(1)-PHNO (n 5 21) were used as template libraries through which the final segmentation was bootstrapped. All 11 subjects who provided a 3T MRI were used as a separate template. Templates were chosen based on representative subject characteristics [Schuetze et al., 2016] . Each subject in the template library was segmented through non-linear atlas-to-template registration followed by label propagation, yielding a unique definition of the subdivisions for each of the templates. The bootstrapping of the final segmentations through the template library results in candidate labels produced for each subject and labels are then fused using a majority vote to complete the segmentation process. Nonlinear registration was performed using a version of the Automatic Normalization Tools (ANTS) registration technique [Avants et al., 2008] that is compatible with the minc toolkit (https://github.com/vfonov/mincANTS). Volumes (mm 3 ) from ROIs were averaged across hemispheres. It is important to note that regional BP ND values and regional volume values are not derived from images warped into the same space. Namely, the BP ND values come from images normalized to MNI space, while the regional volume values do not (labels are propagated into individual subject space, based on a voxel-voting procedure from a large number of candidate labels, using study sample specific templates). Thus, it is highly unlikely that there is overlap in potential variance from differences in "goodness" of r Subcortical Volume and Dopamine Receptors r r 5521 r normalization to the same image space (MNI). Importantly, compared to other automated techniques such as FreeSurfer and FSL, MAGeT-Brain demonstrates the highest correlation with gold-standard manual segmentation techniquesFreeSurfer and FSL significantly overestimate subcortical volumes compared to MAGeT-Brain [Makowski et al., in press] .
Total Brain Volume Analysis
The procedure for total brain volume (TBV) analysis has been published elsewhere . TBV was obtained using the Brain Extraction based on non-local Segmentation Technique (BEaST) method [Eskildsen et al., 2012] , which is based on non-local segmentation in a multi-resolution framework. Each voxel is labeled based on the similarity of its neighborhood of voxels to all the neighborhoods in a library of pre-defined priors, and a non-local means estimator is used to estimate the label at the voxel. Inputs are down-sampled to a lower resolution, segmentation is performed, and results are propagated up to higher resolutions [Eskildsen et al., 2012] . BEaST is designed to include CSF (in the ventricles, cerebellar cistern, deep sulci, along surface of brain, and brainstem), the brainstem, and cerebellar white matter (WM) and GM in the brain mask, while excluding the skull, skin, fat, muscles, dura, eyes, bone, exterior blood vessels, and exterior nerves.
PET Imaging
Subjects were asked to abstain from food for no less than 90 min prior to PET procedures. The radiosynthesis of [ 11 C]-raclopride [Wilson et al., 2000] and [
11 C]-(1)-PHNO [Wilson et al., 2005] , along with the acquisition of PET images [Graff-Guerrero et al., 2010] , has been described in detail elsewhere. Images were acquired on a high-resolution, head-dedicated PET camera system (CPS-HRRT; Siemens Molecular Imaging, USA), which measures radioactivity in 207 brain slices with a thickness of 1.2 mm each. The in-plane resolution was 2.8 mm full-width at half-maximum (FWHM). Transmission scans were acquired with the use of a 137 Cs (T 1/2 5 30.2 years, energy 5 662 KeV) single-photon point source to provide attenuation correction, and the emission data were acquired in list mode. The raw data were reconstructed by filtered back-projection. For the [ 11 C]-raclopride scans (n 5 62), the mean radioactivity dose was 9.75(61.0)mCi, with a specific activity of 1,234.58(6569.11)mCi/mmol, and an injected mass of 3.78(62.19)mg. [ 11 C]-raclopride data were acquired for 60 min and redefined into 28 frames (1-5 of 1-min duration, 6-25 of 2-min duration, and 26-28 of 5-min duration). For the [ 11 C]-(1)-PHNO scans (n 5 68), the mean radioactivity dose was 9.13(61.46)mCi, with a specific activity of 1,100.91(6394.67)mCi/mmol, and an injected mass of 2.15(6.47)mg. None of the participants included in this sample reported nausea given the 
PET Image Analysis
The ROI-based analysis for [ 11 C]-(1)-PHNO has been described in detail elsewhere [Graff-Guerrero et al., 2008; Tziortzi et al., 2011] . Time activity curves (TACs) from ROIs were obtained from the dynamic PET images in native space with reference to each subject's co-registered MRI image. The co-registration of each subjects MRI to PET space was done using the normalized mutual [Lammertsma and Hume, 1996] which has been validated for use with [ 11 C]-(1)-PHNO [Ginovart et al., 2007] . The cerebellum was used as the reference region to derive a quantitative estimate of binding-binding potential relative to the non-displaceable compartment (BP ND )-as defined by the consensus nomenclature for in vivo imaging of reversibly binding radioligands [Innis et al., 2007] . The basis function implementation of the SRTM [Gunn et al., 1997] was applied to the dynamic PET images to generate parametric voxelwise BP ND maps using PMOD (v2.7, PMOD Technologies, Zurich, Switzerland). These images were spatially normalized into MNI brain space by Nearest Neighbor Interpolation with a voxel size fixed in 2 3 2 3 2 mm 3 using SPM2. Regional BP ND estimates were then derived from ROIs defined in MNI space, except for the hypothalamus and ventral pallidum ROIs. The VS and dorsal striatum (dorsal caudate, hereafter caudate, and dorsal putamen, hereafter putamen) were defined according with the criteria of Mawlawi et al [Mawlawi et al., 2001] . The GP ROI was defined according to the criteria of Tziortzi et al [Tziortzi et al., 2011] .
Statistical Analysis
Statistical analyses were conducted using IBM SPSS (v.20; Armonk, NY: IBM Corp) and GraphPad Prism (v.7.0; GraphPad Software, La Jolla California). The relationship between D 2/3 R availability and subcortical volume was explored using partial correlations (two-tailed), controlling for age, gender, and TBV. Four exploratory partial correlation matrices were conducted separately for [ 11 C]-raclopride and [
11 C]-(1)-PHNO (i.e., eight in total). These explored the relationship between BP ND in each ROI and volumes of, (i) striatal subdivisions, (ii) hippocampal subdivisions, (iii) thalamic subdivisions, and (iv) the amygdalaBonferroni correction for multiple comparisons was applied to each correlation matrix individually, and relationships surviving this threshold (P < 0.05 4 n, where Data are presented as Pearson product moment partial correlations (r) with P-values in parentheses. a Significance at P < 0.05 (two-tailed), uncorrected for multiple comparisons (adjusted P-threshold < 0.002). b Significance at P < 0.01 (two-tailed), uncorrected for multiple comparisons (adjusted P-threshold < 0.002). c Survives correction for multiple comparisons (adjusted P-threshold < 0.002).
n 5 # of comparisons) were considered noteworthy. We believe this exploratory, data-driven approach may help guide future studies in developing potential a priori hypotheses, while minimizing potential type-II errors.
RESULTS
Data from 62 subjects scanned with [ 11 C]-raclopride (mean age 5 38.98 6 14.45; 23 female) and 68 subjects scanned with [ Table III and Table  IV, Table V and Table  VI , respectively. While several positive and negative correlations emerged (see Fig. 4 ), none survived correction for multiple comparisons. Adding MRI tesla strength as an additional covariate did not significantly alter the strength of these correlations (data not shown).
For [ 11 C]-raclopride, amygdala volume was not significantly correlated with BP ND in the caudate (r(57) 5 20.11, P 5 0.45), putamen (r(57) 5 20.06, P 5 0.65), VS (r(57) 5 20.11, P 5 0.40), nor the GP (r(57) 5 0.11, P 5 0.41). Adding in the SN (r(63) 5 0.15, P 5 0.24), caudate (r(63) 5 0.14, P 5 0.26), putamen (r(63) 5 0.13, P 5 0.30), VS (r(63) 5 0.05, P 5 0.72), nor the GP (r(63) 5 0.12, P 5 0.34). Adding MRI tesla strength as an additional covariate did not significantly alter the strength of these correlations: SN (r(62) 5 0.15, P 5 0.25), caudate (r(62) 5 0.14, P 5 0.26), putamen (r(62) 5 0.12, P 5 0.35), VS (r(62) 5 0.05, P 5 0.68), and GP (r(62) 5 0.12, P 5 0.36).
DISCUSSION
This investigation is the first to examine how subcortical brain morphology is related to striatal D 2 R and D 3 R availability as measured with both an antagonist and agonist radiotracer. First with the antagonist [ [Woodward et al., 2009] . One exception was the VS, for which there was a positive correlation that did not survive correction for multiple comparisons. However, with the agonist [ 11 C]-(1)-PHNO, BP ND within striatal subregions was generally correlated with the volume of those regions, with the exception of the putamen. Notably, this was especially true for the VS, which survived correction for multiple comparisons.
One potential interpretation of this finding is a causal, biological one. Namely, that the availability of functional D 2/3 R binding sites (i.e., D 2 High) is positively related to striatal size, while the availability of total binding sites (i.e., D 2 High 1 D 2 Low) is not. As [
11 C]-(1)-PHNO is more sensitive to endogenous DA at baseline [Caravaggio et al., 2016a] , an alternative interpretation is that persons with less endogenous DA (and therefore more radiotracer binding) have larger striatal volumes. Another potential interpretation is a methodological one. Namely, that subtle individual variations in striatal size which persist after normalization may influence D 2/3 R availability measures, that is, a partial volume effect (PVE). The PVE is a phenomenon whereby the apparent concentration of a radiotracer decreases as the size of the ROI approaches the instrument resolution (FWHM) [Hoffman et al., 1979] . We suggest it is unlikely that our findings are due to potential PVE. First, PVEs are most pronounced for ROIs 2-3 times smaller than the FWHM [Rousset et al., 1998 ]. It is also a concern for studies of aging, where certain ROIs are known to decrease in size with age. However, the PVE is minimized using the resolution of the CPS-HRRT, and we have not observed significant PVE using other radiotracers in healthy persons with this scanner [Nakajima et al., 2015; Uchida et al., 2011] (1)-PHNO studies using cross-sectional or between group designs. For example, it will be important to determine whether increased [ 11 C]-(1)-PHNO BP ND in obese persons corresponds with concordant increases in striatal volumes [Caravaggio et al., 2015c; Gaiser et al., 2016] .
Notably, [
11 C]-(1)-PHNO BP ND in the dorsal caudate and GP were both correlated with ventral caudate volume. As the dorsal and ventral caudate border each other, it could be argued that this relationship is being driven by spill-over effects. However, with such an interpretation it Data are presented as Pearson product moment partial correlations (r) with P-values in parentheses. a Significance at P < 0.05 (two-tailed), uncorrected for multiple comparisons (adjusted P-threshold < 0.001).
r Subcortical Volume and Dopamine Receptors r r 5527 r would be harder to explain the relationship between GP BP ND and ventral caudate volume. Notably, 65% of the [ 11 C]-(1)-PHNO BP ND signal from the GP reflects D 3 R versus D 2 R [Tziortzi et al., 2011] . While the dorsal caudate and putamen have negligible D 3 R expression, the ventral caudate and putamen express D 3 R (1/3 rd ) . It may be possible that neurons which express D 3 R in the ventral caudate project to those neurons in the internal segment of the GP (GPi) which express D 3 R [Gurevich and Joyce, 1999] . This in turn could potentially drive the relationship between [ 11 C]-(1)-PHNO BP ND in the GP and ventral caudate volume. However, this is speculative and requires substantiation from ex vivo work.
We also explored how D 2/3 R availability in the striatum was related to the volume of other subcortical structures: the hippocampus, thalamus, and amygdala. While none of these correlations survived correction for multiple comparisons, a few notable relationships emerged. First, with [ 11 C]-raclopride there was a negative correlation between VS BP ND and subiculum volume of the hippocampus. The subiculum, which is the main output structure of the hippocampus, projects densely to the nucleus accumbens of the VS [Chase et al., 2015; Groenewegen et al., 1987; Kelley and Domesick, 1982; Lopes da Silva et al., 1984] . It will be important for future in vivo and ex vivo work to elucidate the relationship between the structure and neurochemistry of this pathway. [ 11 C]-raclopride BP ND in the GP was also negatively correlated with the volume of the lateral posterior nucleus of the thalamus. This large nucleus lies medial to the dorsal lateral geniculate nucleus and receives inputs mainly from the superior colliculus-projecting to primary and secondary visual areas [Puelles et al., 2012] . The superior colliculus plays a large role in integrating sensory motor information and, in particular, the generation of saccadic eye movements [Gandhi and Katnani, 2011] . Interestingly, while the GP is involved in motor generation and inhibition in general, the external segment of the GP (GPe) in particular may play an integral role in the generation and suppression of antisaccadic eye movements [Yoshida and Tanaka, 2016] . As the majority of the [ 11 C]-raclopride BP ND in the GP reflects D 2 R in the external segment, our exploratory finding may point to a role for these receptors in saccadic eye movements. While highly speculative, we surmise that future PET studies should examine the relationship between the availability of D 2 R in the GPe and D 3 R in the GPi and saccadic eye movements-measured with [ There are several limitations to the current investigation. First, it has been noted that the injected mass of [
11 C]-(1)-PHNO is not within ideal radiotracer conditions (i.e., <1.5 ng/kg) [Gallezot et al., 2012] . The specific activity required to obtain tracer conditions is not possible with the available radiosynthesis method. While this limitation is currently unavoidable, we attempt to minimize this technical limitation by aiming to control the injected mass of the radiotracer to 2.5 mg (0.02 mg/kg), as previously used Rabiner and Laruelle, 2010; Searle et al., 2013a] . Importantly, our sample (mean injected mass: 2.15 6 0.47mg) did not include any incidence of side effects associated with high [
11 C]-(1)-PHNO injected mass, such as nausea/vomiting Rabiner and Laruelle, 2010] . Second, it has been suggested that [ 11 C]-(1)-PHNO BP ND in D 3 R-rich regions is underestimated if SRTM quantification is used in conjunction with 90 min of data acquisition [Girgis et al., 2011] . Thus, using arterial plasma-based kinetic models following 120 min of emission data is more ideal for quantifying [
11 C]-(1)-PHNO BP ND in D 3 R-rich regions [Girgis et al., 2011] . Moreover, use of arterial plasma-based kinetic models would circumvent limitations associated with using reference tissue methods, namely concerns about specific binding to D 3 R in cerebellar reference tissue [Searle et al., 2013b] . Future [ 11 C]-(1)-PHNO studies would benefit from examining the relationship between D 2/3 R availability and brain morphology using plasma-based modeling and 120 mine emission data. This study was retrospective, reanalyzing previously collected PET data. Thus, other relevant measures such as cognition were not available. Moreover, it would be important to determine how longitudinal changes in D 2/3 R availability with age may be associated with age-related changes in brain morphology in healthy persons and persons with neuropsychiatric disorders. Moreover, it will be important to determine how brain morphology changes and striatal D 2/3 R availability changes relate to each other in addiction. For example, while we did not include heavy drinkers in our study, it would be important to determine how the frequency of alcohol use affects the relationship between in vivo brain morphology measures and DA measures. Finally, it will be important for future studies to examine how brain morphology is related to the in vivo status of other neurochemical systems. For example, increased striatal glutamate levels measured with proton magnetic resonance spectroscopy ( 1 H-MRS) have also been observed in patients with first-episode psychosis [Plitman et al., 2016a] . In turn, striatal glutamate levels were found to be negatively correlated with dorsal caudate volumes in these patients . Given the potential interactions between striatal DA and glutamate [Caravaggio et al., 2016b; Stone et al., 2007] , it can be inferred that the dopaminergic changes observed in schizophrenia may also be related changes in brain morphology. However, without direct evidence this remains merely conjuncture.
While our participants were not taking medications for any serious medical condition, we did not record oral contraceptive use in our female participants. While some [ 11 C]-raclopride PET studies have observed no effect of menstrual cycle on baseline D 2/3 R availability in humans [Farde et al., 1995; Nordstr€ om et al., 1998 ], it is currently unknown whether this may effect [ 11 C]-(1)-PHNO BP ND . Future studies are required to examine the potential interacting effects between menstrual cycle, contraceptive use, and the availability of D 2/3 R using agonist radiotracers in females. Several lines of indirect evidence suggest that striatal DA functioning may differ between men and women. For example, women may be more vulnerable to the reinforcing effects of drugs of abuse [Becker and Hu, 2008; Fattore et al., 2007; Lynch et al., 2002; NolenHoeksema, 2004] . However, PET studies in humans have provided conflicting results as to whether there are sex differences in amphetamine-induced striatal dopamine release [Munro et al., 2006; Riccardi et al., 2006 Riccardi et al., , 2011 . Moreover, some studies suggest that DA transporter availability may not differ between gender, nor across the menstrual cycle [Best et al., 2005] . However, other studies suggests that women may have greater DA transporter functioning in the dorsal striatum [Andersen et al., 2012; Kaasinen et al., 2015; Lee et al., 2015; Wong et al., 2012] , as well as greater DA synthesis capacity in the caudate [Laakso et al., 2002] . While we used sex as a covariate in our main analyses, there may be important sex differences between D 2/3 R availability and brain morphology. For the purposes of transparency, in Supporting Information A, we re-conduct all our exploratory analyses within males and females separately. However, we did not sufficiently sample a large, nor equally matched number of males and females. Thus, interpretation of these data warrants caution and requires replication by sufficiently powered samples in the future.
Elucidating the relationship between metabolic health and striatal D 2/3 R availability remains an on-going and exciting field of exploration in PET [Caravaggio et al., 2015a,c; Dang et al., 2016; Gaiser et al., 2016; Horstmann, 2017] . It is beyond the scope of the current manuscript to review all these conflicting PET findings; considering all the different radioligands used for D 2/3 R, each with their own unique in vivo binding characteristics. Unfortunately, in our current sample, body mass index (BMI) was not collected for all the subjects. Moreover, other relevant markers of metabolic health, such as lipid profiles and insulin resistance, were not collected. In Supporting Information B, we provide the demographics of the subjects who provided BMI. For these subjects, we also re-ran all the analyses of the current investigation using BMI as an additional covariate. Notably, only four subjects scanned with [ 11 C]-raclopride and three subjects scanned with [ 11 C]-(1)-PHNO had BMI's within the moderately obese range (30) (31) (32) (33) (34) (35) . This is unsurprising as having a co-morbid medical condition, such as diabetes or heart disease, was an exclusion criteria for being scanned in this retrospective dataset. Thus, we warrant caution when interpreting these supplementary results. We believe our sample is inadequate to address how obesity modulates D 2/3 R availability r Subcortical Volume and Dopamine Receptors r r 5529 r and brain morphology; we present this Supporting Information for the purposes of transparency, and for guiding future studies which are better poised to address this important topic. Related to metabolic syndrome, several lines of evidence suggest that low-grade systemic inflammation may have an impact on cognition and brain structure [Marsland et al., 2015; Minihane et al., 2015] . While we have tried to screen "healthy" participants, we did not collect peripheral markers of inflammation. Future studies should examine how peripheral inflammatory markerssuch as cytokines, leukocytes, and C-reactive protein levels-relates to concurrent changes in brain morphology and D 2/3 R availability; in healthy persons, persons with neuropsychiatric disorders, and persons with metabolic diseases.
In our sample, PET scans were collected at various times of day. Moreover, we did not record when was the last meal participants had before their PET scans and were only suggested to abstain from food for no less than 90 min prior to PET. To our knowledge, DA release in response to food intake has only been examined with [ 11 C]-raclopride, and methylphenidate was required to be co-administered to see a significant change in BP ND [Volkow et al., 2002; Wang et al., 2011] . However, given the increased sensitivity of [ C]-(1)-PHNO, was related to the volume of several subcortical structures in healthy controls. Such an exploration will, (1) aid the interpretation of future PET findings and (2) help elucidate the relationships between brain chemistry, structure, and function which could be used as potential biomarkers for neuropsychiatric disease. Extension of this work to understand how abnormal in vivo DA functioning relates to brain structure and function in disorders like schizophrenia and food addiction are highly warranted.
